

CURRICULUM VITAE

Anna D. Barker, Ph.D.

Professional Contact Information

Primary

Anna D. Barker, Ph.D.
Chief Strategy Officer
Ellison Institute of Technology
12414 Exposition Blvd
Los Angeles, CA 90064
Phone (323) 442-0393
(503) 703-1945 (Cell)
anna.barker@ellison.usc.edu

Secondary

Distinguished Visiting Fellow, Complex Adaptive Systems
Professor of Practice, School of Life Sciences
Arizona State University
anna.barker@asu.edu
(480) 727-0898 Office
(480) 965-8293 Fax

Personal Contact Information

(Primary address: mail)
6711 E. Camelback Road
Unit 50
Scottsdale, AZ 85251, 5005

(Secondary address – not for mail)
105 Bentwood Court
Cincinnati, Ohio 45241
Annbarke1@aol.com
(Personal email address)
Annbarke1@aol.com
(503) 703-1945 (Cell)

PROFESSIONAL BIOGRAPHICAL SUMMARY

Dr. Barker has a long and successful history in research and the leadership and management of discovery, translation, clinical research, and development in the academic, non-profit, and private sectors. She currently serves as the Chief Strategy Officer for the Ellison Medical (EMI) and as a Distinguished Visiting Fellow and Professor of Practice at Arizona State University (USC).

Dr. Barker currently leads the strategic planning and implementation of research and development of strategic scientific Initiatives and programs at the Ellison Medical Institute (EMI). The Institute is comprised of two operating units in the US (Los Angeles) and the UK (Oxford, UK). The overall vision of the EMI is to improve the prevention, diagnosis, and treatment of patients with cancer and other complex diseases through medical research and clinical care. More specifically the EMI mission is to generate, curate and integrate high quality data to advance a new generation of artificial intelligence-based (and other technologies) advances that will provide a foundation for precision medicine, especially precision oncology.

In her previous role as Co-Director of Complex Adaptive Systems Initiative (CASI) at ASU, Dr. Barker created transformative knowledge networks to pursue solutions to key problems in oncology and other complex diseases. The mission of one such network, the National Biomarker Development Alliance (NBDA), was founded to collaboratively create the standards and processes needed to support end-to-end systems-based biomarker development. Biomarkers are critical to achieving molecularly based medicine, but most have historically failed in regulatory review. These failures are also tied to the lack of successful companies in the molecular diagnostics industry. As a result of the NBDA's progress in both biomarker development tied to innovative clinical trials (adaptive platform trial models) she was invited to lead the 21st Century Cures group that developed the recommendations for these areas that were ultimately included in the legislation. The legislation empowered the FDA to pursue guidance in biomarker development and innovative clinical trials that is advancing progress for patient benefit.

Dr. Barker routinely seeks to solve what seem to be intractable problems in biomedicine through think tanks and workshops that engage relevant experts. In the past few years, she has engaged over 2000 scientists and clinicians to explore solutions to problems in biomarker development, clinical trials design, artificial intelligence in precision medicine, evolution and cancer and several other problem areas. Potential solutions are pursued through demonstration projects. For example, a think tank on the dearth of progress in glioblastoma (GBM), the deadliest of adult brain tumors, prompted her to assemble 130 of the leading scientists in the field to design an advanced clinical trial for GBM. Nearly two years of crowdsourcing information from various fields led to the design of a trial named GBM AGILE (adaptive, global, innovative, learning environment). The trial was launched in early 2019. The design of GBM AGILE was repurposed for a similar trial in pancreas cancer.

Dr. Barker has long focused on facilitating innovation in scientific discovery and development tied to clinical benefit in cancer (and other complex diseases). While Principal Deputy Director of the National Cancer Institute (NCI) and Deputy Director for Strategic Scientific Initiatives, Dr. Barker led the planning, development and implementation of a number of strategic scientific and advanced technology initiatives and novel partnerships, including: The Cancer Genome Atlas (TCGA), co-developed with the National Human Genome Research Institute); the NCI Clinical Proteomics

Technology Initiative; the Nanotechnology Alliance for Cancer; the Physical Sciences Oncology Centers; and several others. She also enabled the development of NCI foundational programs in biospecimen science and bioinformatics and was the founding co-chair of the NCI-FDA Interagency Task Force and the Cancer Steering Committee of the Foundation for the NIH Biomarker Consortium. Dr. Barker also led the NCI's international efforts and established new research programs and partnerships in China and South America.

Prior to joining the NCI, Dr. spent several years in the non-profit research foundation and private sectors where she advanced from a principal research scientist to become an executive at Battelle Memorial Institute. In her years at Battelle, a non-profit research foundation, she developed and led an operational unit that consisted of scientists, engineers, clinicians, and technical staff including molecular biology; drug discovery and development; pharmacogenomics and toxicology; immunotherapy; advanced chemistry platforms; environmental sciences; mathematical modeling; and clinical trials. Under her leadership, Battelle engaged with the NCI beginning in the 1970's to complete several innovative (and ultimately transformative) programs, including:

- Complex in vivo studies to establish the toxicological profile of the anthracyclines (Adriamycin).
- New mass spectrometry (MS) based pharmacologic models for oncology drug evaluation and measurement of proteins in complex diseases:
- Deployment of a tiered large scale screening system to identify moieties for study by the NCI's Developmental Therapeutic Program (DTP).

In her tenure at Battelle, Dr. Barker (and Battelle) also partnered with and co-funded with the NCI to design and build the first large scale athymic mouse colony and state-of-the-art facility to study in vivo cancer models free of immunologic rejection. She also worked collaboratively with Battelle and NCI colleagues to develop human tumor xenograft models for breast, colon, lung, and other cancers. Finally, due to her cancer research work and experience working with several of the NCI's drug discovery and development programs, Battelle was awarded a master agreement to manage the NCI's drug development programs. In this role she oversaw a large group of Battelle staff (located in Washington, D.C. for over a decade) and coordinated all aspects of what became the first integrated effort to develop cancer drugs.

In the biotechnology sector, Dr. Barker served as the CEO of a diagnostics company that focused on the development and sale of assays for the therapeutic drug monitoring markets. Through merger and acquisition, the company transitioned into a public company in 1994- listed on both the NADDAQ (U.S.) and the French Nouveau Marché exchanges. The Company, which she co-founded, OXIS International, Inc., focused on the discovery and development of biomarkers and experimental therapeutics to assess and control reactive oxygen damage. Under her leadership, the company advanced two series of molecules into clinical trials and developed a series of biomarkers for the research market to assess various aspects of oxidative stress.

A defining aspect of Dr. Barker's career has been and continues to be service dedicated to accelerating progress against cancer through research and advocacy. Some examples include: Co-Founder and Director, National Biomarker Development Alliance (NBDA); Member of the Scientific Advisory Group (Defeat GBM), National Brain Tumor Society; Board of Directors, Friends of Cancer Research; Board of Directors, Quantum Leap Foundation; founding partner and member of the Board of Directors, and Chairperson of the Research Team of C-Change organization

(formally the National Dialogue on Cancer); Founding member and Chairperson of the Department of Defense (DOD) Breast Cancer Research Program (BCRP); several capacities for the American Association for Cancer Research (AACR), including, two terms on the Board of Directors, and chairperson of the Public Science Policy, and Legislative Affairs Committee for over 10 years, founder and current chairperson of the AACR's Scientist Survivor Programs, and service on numerous award and other committees, to name a few. In 1998, Dr. Barker served on the Board of Directors for "The March – Coming Together to Conquer Cancer," co-chaired The March Research Task Force, and co-developed the Report from "The March" Research Task Force, which was presented to Congress and subsequently published in Cancer Research.

Prior to her period of government service, Dr. Barker served in several capacities for the NCI including membership on the NCI's Board of Scientific Counselors, Division of Cancer Etiology; service on special study sections; and member and as Chairperson of the Cancer Center Support Review Study Section for several years. She currently serves as a member of the National Cancer Advisory Board.

Dr. Barker has received numerous awards for her contributions to research, cancer patients, professional and advocacy organizations, and the ongoing national effort to prevent and cure cancer.

Dr. Barker earned her undergraduate M.S. degree from Morehead State University. She completed her M.A. and Ph.D. degrees at the Ohio State University, where she trained in immunology and conducted research on the differentiation of leukemic T-cells and immunotherapy of hematologic malignancies. Her research interests currently include complex adaptive systems science and models, data science and AI, convergence science – biological and physical sciences and intervention strategies for complex diseases associated with reactive oxygen species (ROS) damage.

CURRICULUM VITAE

Anna D. Barker, Ph.D.

EMPLOYMENT/APPOINTMENTS HISTORY

Chief Strategy Officer, Ellison Medical Institute, 2019 – Present
Distinguished Visiting Fellow, Complex Adaptive Systems and Professor of Practice, Arizona State University (ASU), 2019 – Present
Co-Director, Complex Adaptive Systems, Director, Transformative Healthcare Networks and Director, Transformative Healthcare Network, Professor (Practice, School of Life Sciences, Arizona State University (ASU), 2011 - Present
Co-Founder and Director, National Biomarker Development Alliance (NBDA), A Non-Profit, start-up funding from ASU and hosted by the ASU Foundation, 2014 - Present
Strategic Consultant, Inova Translational Medicine Institute, January - July 2011
Principle Deputy Director and Deputy Director for Strategic Scientific Initiatives, National Cancer Institute, Bethesda MD, 2002 -2010 (Retired from government service)
President, Chief Executive Officer, BIO-NOVA, Inc., (Private), Portland, OR, 1998 – 2002
President, Chief Executive Officer, OXIS International, Inc., (Public), Portland, OR, 1994-98
President, Chief Executive Office, International BioClinical, Inc., (Private), Portland, OR, 1991-1994
Senior/Group Vice President and General Manager, Health and Environment Groups, Battelle, Columbus, OH, 1989-1990 (Retired)
Senior Vice President, Battelle Technology International, Biological and Chemical Sciences Technical Center, Columbus, OH, 1985-1989
Department Manager, Biological Sciences Department, Battelle Columbus Laboratories, Columbus, OH, 1979-1985
Section Manager, Biomedical Sciences Section, Battelle Columbus Laboratories, Columbus, OH, 1975-1979
Associate Section Manager, Biomedical Sciences Section, Battelle, Columbus Laboratories, Columbus, OH, 1974-1975
Senior Research Immunologist, Battelle Columbus Laboratories, Columbus, OH, 1973-1975
Research Immunologist, Battelle Columbus Laboratories, Columbus, OH, 1972-1973
Research Associate, Microbiology, Ohio State University, Columbus, OH, 1971- 1972
National Science Foundation Fellow, Microbiology, Ohio State University, Columbus, OH, 1970-1971
Research Associate, Microbiology, Ohio State University, Columbus, OH, 1969-1970
Muellhaupt Fellow, Microbiology, Ohio State University, Columbus, OH, 1968-1969
Instructor, Advanced Chemistry, Columbus Public School, Columbus, OH, 1963-1968
Teaching Assistant, Chemistry and Microbiology, Morehead State University, 1962-1963

EDUCATION

B.S. Morehead State University, 1963
M.A. The Ohio State University, 1967
Ph.D. The Ohio State University, 1971

**SCIENCE/TECHNOLOGY LEADERSHIP/MANAGEMENT EXPERIENCE:
(PRIVATE AND NON-PROFIT SECTORS)**

- Comprehensive Research and Development Strategies
- Operations Management
- Strategic and Business Planning and Implementation
- Financial Management
- Alliance/Partnership Development
- Large Project Management
- Team Building and Group Facilitation
- Diagnostics Development and Commercialization
- Therapeutics Development and Clinical Trials
- Regulatory Strategies and Filing(s)
- Private and Public Biotechnology Company Development and Financing

**SCIENCE AND TECHNOLOGY LEADERSHIP/MANAGEMENT
(EXAMPLES FROM GOVERNMENT SECTOR/SERVICE)**

- Complex Adaptive Systems – Biomedicine – viewing, modeling, and managing Cancer as a CAS to achieve precision medicine.
- Genomics, Designed and oversaw operations of The Cancer Genome Atlas Cancer
- Proteomics, Oversaw design and operations of the NCI's National Proteomics Initiative
- Biospecimen Science, Oversaw development of NCI's Best Practices for biorepositories and biospecimen science.
- Nanotechnology, Oversaw design and operations of the NCI's Nanotechnology Alliance
- Convergence, Oncology- Physical Sciences, Oversaw the Design and Operations of the NCI's Physical Sciences Oncology Centers
- Innovation in Oncology Drug Development, Co-founder, and Co-Chair the NCI-FDA Interagency Task Force (outcomes such as the Exploratory IND, Phase 0 trial)
- Biomarkers and Innovative Clinical Trials Models, Co-chaired the FNIH Cancer Steering Committee, Co-Chaired the design committee for the ISPY - 2 trial.

PRIVATE COMPANY BOARD SCIENTIFIC BOARD MEMBERSHIPS

- Calviri (ASU startup company), Board of Directors, 2016-2020
- Caris Life Sciences, Scientific Advisory Board member, 2014-Present
- Oncology Research for Control Applications (ORCA) Biosciences, Inc., Seattle, WA, Board of Directors, 1998-2001
- Nutrilogics Inc., Scientific Advisory Board, 1999 -2001
- OXIS International, Inc., Portland, OR, Board of Directors, 1994-1998

- Bioxytech, S.A., Paris, France Chairperson, Board of Directors, 1995-1998

***NON-PROFIT and FEDERAL BOARD MEMBERSHIPS
(PUBLIC/PROFESSIONAL SERVICE)***

- **National Cancer Advisory Board, National Cancer Institute, Member, 2020 – 2024**
- **National Cancer Advisory Board, Planning and Budget Subcommittee, Chairperson, 2020-Present**
- **Sanford Burnham Prebys Medical Discovery Institute, Board of Trustees Member, 2018 – 2021**
- **Friends of Cancer Research Board of Directors, 2010 – Present**
- **SAGE Bionetworks, Scientific Advisory Board Member, 2018-Present**
- **Pancreatic Cancer Action Network, Precision Promise Trial, DSMB Member, 2018-Present**
- **National Biomarker Development Alliance (NBDA), Member of the Steering Committee Scientific Advisory Committee, 2014 - Present**
- **Quantum Leap Board of Directors, 2010 – Present**
- **Mathematical Biology Institute, Board of Directors, Ohio State University, 2012 - 2017**
- **American Association for Cancer Research, Board of Directors, 1999-2001**
- **American Association for Cancer Research, Board of Directors, 1995-1997**
- **National Dialogue on Cancer/C-Change, Member, Board of Directors, 2001-2009**

HONORS AND AWARDS

- **Inaugural Beacon Award for Women Leaders in Oncology, 2022, AIM-HI (National Foundation for Cancer Research)**
- **AACR Distinguished Service Award for Exceptional Leadership in Cancer Research, Science Policy, and Advocacy, 2022, AACR's 115th Anniversary**
- **Election as a Fellow of the AACR Research Academy, Class of 2021, FAACR, The American Association for Cancer Research**
- **Presidentially Appointed to the National Cancer Advisory Board, 2020 - Present**
- **Team Science Award, Co-Founder, The Cancer Genome Atlas, (with Dr. Francis Collins), American Association for Cancer Research, Founders Award, 2020**
- **Distinguished Award for Exceptional Leadership in Cancer Science Policy and Advocacy, American Association for Cancer Research, 2018**
- **23rd. Annual Cancer leadership Award, Ellen V. Sigal Advocacy Leadership Award, Friends of Cancer Research, 2019**
- **Chairman, Biomarkers and Clinical Trials Sections, 21st Century Cures Legislation, 2015-16**
- **Senior Fellow, Faster Cures, Center of the Milken Institute, 2014-Present**
- **CFA Culling Memorial Lecture Award, National Society of Histotechnology. August 2014**
- **Distinguished Alumni Award, Distinguished Achievement Award, The Ohio State University, College of Arts and Sciences, 2014**
- **Margaret Foti Award for Extraordinary Contributions and Leadership in Cancer Research, American Association for Cancer Research, 100th Anniversary Meeting, 2009**

- Named to the list of “The **100 People Changing America**” by Rolling Stone Magazine, 2009
- **Research Excellence Award (TCGA)**, 2009, National Brain Tumor Society
- **Public Service Award** (Shared with Dr. Janet Woodcock FDA), Friends of Cancer Research, 2004
- **Frances Prescott Award for Breast Cancer Research and Advocacy**, Vanderbilt University, 2003
- **Cancer Crusaders Award**, Congressman J.C. Watts, Jr., 1999
- **Named Fellowship Award** (Anna D. Barker Basic Cancer Research Fellowship), American Association for Cancer Research, 1999 - Present
- **Public Service Award**, American Association for Cancer Research, 1998
- **The Harriet H. Parker Award for Science and Technology**, YWCA, Women of Achievement Awards, 1987
- **Pilot Club, Woman of the Year Award**, 1985
- **Outstanding Alumnus Award (Hall of Fame)**, Morehead State University, 1979
- **Ten Outstanding Young Citizens Award** (Columbus, OH), Junior Chamber of Commerce, 1976
- **National Science Foundation Fellowship**, 1970-71
- **Muellhaupt Fellowship**, 1968-69

SCHOLARSHIPS AND FELLOWSHIPS

- **National Science Foundation Fellowship**, 1970-71
- **Muellhaupt Fellowship**, 1968-69
- **Harbison Walker Undergraduate Scholarship**, 1959-63

COMMITTEE/BOARD/CHAIR APPOINTMENTS (PUBLIC AND PROFESSIONAL SERVICE)

- **American Association for Cancer Research (AACR):**
 - Appointment to the AACR Scientific Advisory Council, 2025
 - Chair, Strategic Planning Committee, 2025
 - Chair, Standing Finance Committee, AACR, 2024 - Present
 - Chair, Oncology Development Fund Committee, 2023 – Present
 - Election as a Fellow of the AACR Research Academy, Class of 2021
 - Co-Founder Cancer Evolution Work Group and Co-Chair Executive Committee 2022-2025
 - Founder and Chair, Scientist Survivor Program, 1999 – Present
 - Co-Chair, Conflict of Interest Work Group, 2018 - Present
 - Member, AACR Finance and Audit Committee, 2019 – Present
 - Co-Chair, Conflict of Interest Work Group, 2018 – Present
 - Member, Science Policy and Legislative Affairs Committee, 2010-Present
 - Member, Board of Scientific Advisors, 2010 – Present
 - Co-Chair and Co-Chair, Organizing Committee, AACR Special Conference, Cancer Translating Cancer Evolution and Data Science: The Next Frontier, December 3 -6, 2023.

- Chair, Plenary session, Cancer Evolution, 2022 Annual Meeting
- Panel Discussion, Lessons Learned, 2021 COVID 19 AACR Meeting
- SSP Virtual Meeting Chair, AACR Annual Virtual Meetings, 2020-2021
- Special Conferences Committee, 2007-Present
- Margaret Foti Award Committee 2019 and Multiple Years
- Team Science Award Committee, Multiple Years
- Annual Meeting Committee, 2019 and Multiple Years
- Member, Cancer Progress Report Committee, 2010-2016
- Board of Directors, 1999-2001
- Board of Directors, 1995-1997
- Science Policy and Legislative Affairs Committee (Formerly the Public Education Committee), 1990- 2002
- Science Policy and Legislative Affairs Committee (Public Education Committee),
- Chairperson, 1993-2002
- Public Relations Committee, 1998-2002
- Development Committee, 1991 - 2002
- Development Committee, 1998-2002
- Corporate Support Committee, Chairperson, 1991 – 98
- Ad Hoc Committee - Public Forum, Chairperson, 1997 – 2008
- Ohio State Legislative Committee, 1990-93
- Oregon State Legislative Committee, 1993 - 2002
- NCI Affairs Committee, 1993-96
- Ad Hoc Committee on By Laws Revision, 1999
- Steering Committee on the War on Cancer, Chairperson, 1998
- Rhodes Award Committee, Member, 1990-91
- Task Force on Experimental Therapeutics, 1991-93
- Program Committee, Member, 1988-89
- Program Committee, Biology Chairperson, 1989-90
- AACR Representative to the National Coalition for Cancer Research, 1995 – 2002
- **Board of Electors, Member, Sigma Xi, 1978**
- **Fred Hutchinson Cancer Center:**
 - External Advisory Board, Member, 1993-1999
 - Molecular Medicine Review Board, Member, 1993-98
- **Internal Scientific Review Committee, Member, Riverside Methodist Hospital, 1978-82**
- **International Congress Reticuloendothelial Society, Resources Committee, Chairperson, 1978**
- **National Cancer Institute:**
 - Special Volunteer, Physical Sciences, Oncology Initiatives, September 2010-2016
 - Division of Cancer Etiology, Board of Scientific Counselors, Member, 1986-90
 - Ad Hoc Construction Review Committee, Member, 1984-85
 - Investigator Grants (OIG), Study Section, Member, July 1984
 - Committee on Care and Use of Laboratory Animals, The National Academy of Sciences, Member, 1983-84
 - Developmental Therapeutic Contracts Review Committee, Member, 1983-85
 - Cancer Center Support Review Committee, Member, 1976-79
 - Cancer Center Support Review Committee, Chairperson, 1978-79

- **National Cancer Legislative Action (NCLAC) Committee, Member, 2000-2002**
- **National Coalition for Cancer Research (NCCR), AACR-Representative and Member Board of Directors, 1993-2002**
- **National Dialogue on Cancer (Re-named C-Change):**
 - Founding Member, Steering Committee, 1998
 - Member, Board of Directors, 2001-2009
 - Collaborating Partner, 1999-Present
 - Member, Annual Meeting Planning Committee, 2007- Present
 - Co-Chairperson, Public Sector Research Team, 1999-2000
 - Chairperson, NDC Cancer Research Team – 2000 - 2004
- **Ohio Cancer Research Associates, Inc.**
 - Scientific Review Committee, Member, 1988-Present
 - Board of Trustees, Member, July 1984- 2000
- **Ohio State University Cancer Center, Internal Scientific Review Committee, Member, 1976-78**
- **Oregon Biotechnology Association (OBA), Board of Directors, Member, 1998- 2002**
- **Oregon Laser Medical Center (OLMC), Board of Directors, Member, Providence/St. Vincent's Hospital, 1997-2002**
- **Research and Development Editorial Board, Member, 1988-1998**
- **THE MARCH – Coming Together to Conquer Cancer – Vice Chairperson and Member of the Board of Directors, 1998 – 2000**
- **THE MARCH Research Task Force, Co-Chairperson, 1998 -99**
- **USAMRDC Breast Cancer Research Program**
 - Founding Integration Panel, Member, 1993- 2005
 - Integration Panel, Chairperson, 1995-96
 - Integration Panel Chair Emeritus, 1997-99
 - Executive Committee Member, 1997- Present
 - Era of Hope Meeting, Program Planning Committee Member, 1998, 2000, 2004
- **Foundation for the National Institutes of Health, Biomarkers Consortium**
 - Co-Chairman, Cancer Steering Committee, 2006-2010
 - Co-Chairman, ISPY-2 Planning Committee, 2007-2009
 - Co-Chairman, ISPY-2 Oversight Team, 2010-Present
- **National Foundation for Cancer Research (NFCR)**
 - Member Beacon Award, Women Leaders in Oncology Review Committee 2023-24
 - Reviewer, NFCR – AIMH Impact Venture Capital Awards for Start-Up Biotech Companies (2023-25)
- **Quantum Leap Healthcare**
 - Member Board of Directors, 2007 – Present
 - Member, Compensation and Governance Committees, 2018-Present
 - Chair, National I-SPY Trials Oversight Committee – 2009 - Present

PROFESSIONAL MEMBERSHIPS

- American Association for Cancer Research

- American Association of Immunologists
- American Society for Microbiology
- Sigma Xi
- International Association for Comparative Research on Leukemia and Related Diseases

**RECENT INVITED AND KEYNOTE PRESENTATIONS, CONGRESSIONAL TESTIMONY
(EXAMPLES FROM A FEW YEARS – (Not Updated))**

- *Keynote Presentation, Eighth Annual University of Cincinnati Cancer Center (The Next Frontier in Cancer Detection & Diagnostics), Title, "The Challenges of Developing Clinically Relevant, Robust Biomarkers" August 27, 2021*
- *AACR Annual Meeting, 2019, Symposium Viewing and Managing Cancer as a Complex Adaptive System, Viewing and Managing Immunotherapy as a Complex Adaptive System*
- *American Association for the Advancement of Science, February 16, 2018, Evolution and Cancer, AAAS Annual Meeting Austin, TX*
- *Keynote Presentations, Prostate Cancer Foundation (28th Annual Scientific Retreat), The Past, Present and Future of Cancer Research, Title, Oncology: A Storied Past and Portentous Future*
- *Fortune Brainstorm HEALTH Conference, March 20, 2018, The Future of Immunotherapy, Laguna Niguel, CA*
- *AACR Annual Meeting 2018, Distinguished Service Award Lecture, Cancer Biomarkers: Moving from Promise to Reality", April 13-18, 2018, Chicago, IL*
- *National Academy of Medicine, Cancer Control Public Workshop, How to Transform Cancer Control, What Should We Be Doing Differently? June 6-7, Washington, D.C.*
- *Press Event, September 12, 2018, The Impact of the Revolutionary I-SPY 2 Trial on Early, High-Risk Breast Cancer Treatment: The Future of Clinical Trials, Washington, DC*
- *University of Arizona, Research Symposium, Biomarkers an Evolving Story of Possibilities vs. Challenges, December 6, 2018, Phoenix, AZ*
- *FasterCures (Milken Institute) Webinar, So You Want to Start a Master Protocol Trial, December 10, 2018*
- *DIA (Drug Information Association) – Medical Affairs and Scientific Communications Forum, and Collaboration: Forces Shaping the Future of Precision Medicine, Complexity, Convergence March 14, 2017, Tucson, AZ*
- *Arizona Bio Expo, Is Innovation our Best Hope to Achieve a New Generation of Precision Medicine? The Future of Precision Medicine, March 29, 2017, Phoenix, AZ*
- *Fortune Brainstorm Health, May 3, The Liquid Biopsy, 2017, San Diego, CA*
- *Precision Medicine Leadership Summit, Biomarkers for Precision Medicine, August 22, 2017, San Diego, CA*
- *Annual Schuellein Award Lecture in Biology, Embracing Complexity: Enabling the Convergence of the Biological, Physical, Mathematical and Engineering Sciences to Create a New Generation of Biomedicine, November 30, 2017, University of Dayton, Dayton, OH*
- *NEWDIGS Next Wave Forum, Evolution of Adaptive Platform Trials: Lessons Learned – So far, December 13, 2017, MIT, Cambridge, MA*

- Milken Institute Global Conference. Panel: The Promise of the Cancer Moonshot. May 1-4, 2016. Beverly Hills, CA
- American Physical Society (APS) Meeting. Why is Physics Important to Cancer Research? Session: The Fight Against Cancer: Physics Enters the Fray. March 14-18, 2016. Baltimore, MD.
- Milken Institute Public Health Summit. Panel: Big Data, Small Devices: How Technology is Advancing Public Health. February 29-March 3, 2016. Washington, D.C.
- Personalized Medicine World Conference 2016. Where Have All the Biomarkers Gone? Session: From Biomarkers to Clinical Diagnostics. January 24-27, 2016. Silicon Valley, CA.
- CBS This Morning. Promising New Ways to Prevent and Treat Cancer. Interview. January 6, 2015. New York, NY.
- NBDA Workshop VII – Collaboratively Building a Foundation for FDA Biomarker Qualification. December 14-15, 2015. Washington, D.C.
- Harvard 11th Annual Personalized Medicine Conference. Role of Biomarker Qualification in Personalized Medicine. Keynote Presentation. November 18, 2015. Boston, MA.
- Press Conference to Announce GBM AGILE trial. November 12, 2015. Washington, D.C.
- National Cancer Research Institute (NCRI) Conference. Viewing Cancer as a Complex Adaptive System. Plenary Presentation. November 1-4, 2015. Liverpool, UK.
- LabRoots' 3rd Annual Cancer Research & Oncology Conference. Biomarkers: An Auspicious Beginning and a Portentous Future? Keynote Session: Targeted, precision therapies for advanced disease. September 30, 2015. Virtual Event.
- Nation Society of Histotechnology Annual Meeting, The CFA Culling Memorial Lecture Award, August 25, 2014 (Award Lecture)
- 8th IUPAP International Conference on Biological Physics, International Union of Pure and Applied Biological Physics, June 2014, Beijing, China (Invited Keynote Presentation)
- Diagnostics Summit – Innovative Pathways to Better Health / DXInsights – University of Arizona, Tucson, AZ, May 5, 2014 (Keynote Presentation, Invited)
- Innovation in Evidence Development for Molecular Diagnostics, ASU, April 3, 2014 (Keynote Presentation, Invited)
- PINTAD Meeting. Pharma Imaging Network for Therapeutics and Diagnostics. March 28, 2014.
- Lawrence Berkeley National Laboratory. Life Sciences Division 2013-14 Seminar. February 11, 2014. Berkeley, CA.
- CDC Atlanta Summit on Public Health & Prosperity. Panel: The Art of Alignment: Nonprofit Strategies for Improving Public Health. January 30-31, 2014. Atlanta, GA.
- NBDA Press Launch. January 13, 2014. Washington, D.C.
- National Academy of Sciences, Implementing Convergence in Life Sciences, Washington, D.C., September 2013,
- (Keynote Presentation Invited) BioConference Live. LabRoots, Inc., Is Personalized (Molecularly Based) Medicine Our Best Hope to Finally Defeat Cancer?" October 6, 2013
- GlaxoSmithKline Innovation and Integration Summit, Philadelphia, September 2013 (Keynote Presentation, Invited)
- International Biannual Evolution and Cancer Conference, San Francisco, June 2013 (Keynote Presentation, Invited)

- Association of Public and Land Grant Universities Council on Research Policy and Graduate Education, Big Data, Complexity and the Emergence of Molecularly Based Medicine, June 2013 (Keynote Presentation, Invited)
- AACR Congressional Briefing, Cancer Progress Report, February 2013, (Invited Speaker)
- U.S. China Symposium, State-of-the-Science for Cancer Research and Future Directions for Global Collaboration, Beijing, China, November 2012 (Keynote Presentation, Invited)
- Research Symposium, national Brain Tumor Society, October 2012, Boston (Keynote Presentation, Invited)
- Oncology at the Limits (London UK – Royal College of Physicians, October 2012, London, ((Keynote Presentation, Invited)
- Cancer Clinics of Excellence 5th Annual Clinical Summit, May 2012, Ft. Lauderdale (Keynote Presentation, Invited)
- American Physics Society, Physics of Cancer, February 2012 (Invited Tutorial)
- 2010 Translational medicine Forum, “What Will It Take to Get Advances from 21st Century Science to Patients” – “Reflections on 8 Years at the NCI”, Washington, DC, October 2010 (Invited Presentation)
- TEDMED Invited Lecture, TEDMED Annual Meeting, “Can the Government Cure Cancer? San Diego, CA, October 2010.
- Complex Adaptive Systems Institute, Arizona State University, Innovation Demands Boldness, “The Challenges of Developing and Implementing Large Scale and/or Innovative Programs in Biomedicine, September 2010 (Invited Presentation)
- Understanding Cancer Via the Theoretical Sciences, The Princeton Center of Theoretical Sciences, “The Complexity of Cancer: Challenges and Opportunities for the Physical Scientists,” Princeton, NJ, April 2010(Keynote Presentation, Invited)
- Congressional Testimony: Primary Witness for the National Cancer Institute, Subcommittee on Health, Committee on Energy and Commerce, United Primary Witness for the National Cancer Institute, Subcommittee on Health, Committee on Energy and Commerce, United States House of Representatives. “National Cancer Institute Research: Today’s Progress; Tomorrow’s Challenges,” Tuesday, March 23, 2010.
- Enabling a Future of Personalized Cancer Medicine: Leveraging 30 Years of China-US Scientific Progress- “Pathways to Personalized Cancer Medicine through China-US Cooperation”, Beijing, China, November 2009 (Co-organizer and Invited Keynote Presentation)
- Analytical & Life Science Systems Association 2009 Senior Management Conference, “The Outlook for Cancer Research – The NCI’s View”, Laguna Beach, CA, October 2009 (Keynote Presentation, Invited)
- Accelerate Brain Cancer Cures, “Symposium - How do we Most Effectively Discover, Develop and Bring to the Market New Treatments for Brain Cancer Patients? “The Cancer Genome Atlas: Recent Progress in GBM,” Sausalito, October 2009 (Invited Presentation)
- Center for Cancer Nanotechnology Excellence Symposium, “Leveraging Nanotechnology to Accelerate Progress Against Cancer”- Stanford, CA, May 2009 (Keynote Presentation, Invited)

- AACR Annual Meeting, “Cancer Diagnostics Using Nanotechnology Platforms: Challenges & Opportunities” – Denver, CO, April 2009 (Invited Presentation)
- AACR Industrial Roundtable – “Status of the Cancer Genome Sequencing,” Phoenix, AZ, February 2009 (Invited Presentation)

*Routinely delivered 8-10 invited/keynote presentations per year while Deputy Director of the NCI.

PEER-REVIEWED PUBLICATIONS AND ABSTRACTS

Recent Publications

- **Barker AD**, Alba MM, Mallick P, Agus DB, Lee JSH. An Inflection Point in Cancer Protein Biomarkers: What was and What's Next. *Mol Cell Proteomics*. 2023 Jul;22(7):100569. doi: 10.1016/j.mcpro.2023.100569. Epub 2023 May 16. PMID: 37196763; PMCID: PMC10388583.
- **Barker, A.D.**, and Lee, JSH. Translating “Big Data” in Oncology for Clinical Benefit: Progress or Paralysis. *Cancer Res* 1 June 2022; 82 (11): 2072–2075. <https://doi.org/10.1158/0008-5472.CAN-22-0100>
- Angus, D.C., Alexander BM., Berry S., Buxton M., Lewis R., Paoloni M., Webb SAR., Arnold S., **Barker A.,D.**, Berry DA., Bonten MJM., Brophy M, Butler C., Cloughesy TF., Derde LPG., Esserman LJ., Ferguson R., Fiore L., Gaffey SC., Gaziano JM., Giusti K, Goossens H, Heritier S, Hyman B, Krams M, Larholt K, LaVange LM, Lavori P, Lo AW, London AJ, Manax V, McArthur C, O'Neill G., Parmigiani G., Perlmutter J., Petzold EA., Ritchie C., Rowan KM., Seymour CW., Shapiro NI., Simeone DM., Smith B., Spellberg B., Stern AD., Trippa L., Trusheim M, Viele K., Wen PY., Woodcock J. Adaptive platform trials: definition, design, conduct and reporting considerations. **Nature reviews. Drug Discovery**. 2019 Oct;18(10):797-807. DOI: 10.1038/s41573-019-0034-3.
- The Adaptive Platform Trials Coalition: Derek C. Angus, Brian M. Alexander, Scott Berry, Meredith Buxton, Roger Lewis, Melissa Paoloni, Steven A. R. Webb, Steven Arnold, **Anna Barker**, Donald A. Berry, Marc J. M. Bonten, Mary Brophy, Christopher Butler, Timothy F. Cloughesy, Lennie P. G. Derde, Laura J. Esserman, Ryan Ferguson, Louis Fiore, Sarah C. Gaffey, J. Michael Gaziano, Kathy Giusti, Herman Goossens, Stephane Heritier, Bradley Hyman, Michael Krams, Kay Larholt, Lisa M. LaVange, Philip Lavori, Andrew W. Lo, Alex John London, Victoria Manax, Colin McArthur, Genevieve O'Neill, Giovanni Parmigiani, Jane Perlmutter, Elizabeth A. Petzold, Craig Ritchie, Kathryn M. Rowan, Christopher W. Seymour, Nathan I. Shapiro, Diane M. Simeone, Bradley Smith, Bradley Spellberg, Ariel Dora Stern, Lorenzo Trippa, Mark Trusheim, Kert Viele, Patrick Y. Wen and Janet Woodcock. Adaptive platform trials: definition, design, conduct and reporting considerations. (2019), *Nature Reviews Drug Discovery* 18(10), 797-807. <https://doi.org/10.1038/s41573-019-0034>

- Alexander, B., Ba, S., Berger, M., Berry, D., Cavenee, W., Chang, S., Cloughesy, T. Jiang, T., Khasraw, M., Li, W., Mittmaa, R., Poste, G., Wen, P., Yung, W.K.A., **Barker, A.**, on behalf of the GBM AGILE Network. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. **Clinical Cancer Research**. February 2018. 15; 24(4): 737-743.
- Domenyuk, V., Gatalica, Z., Santhanam, R., Wei, X., Stark, A., Kennedy, P., Toussaint, B., Levenberg, S. Wang, J., Xiao, N. Greil, R., Rinnerthaler, G., Gampenrieder, S., Heimberger, A., Berry, **D. Barker, A.**, Quackenbush, J. Marshall, J., Poste, G., Vacirca, J. Vidal, G., Schwartzberg, L., Halbert, D., Voss, A., Magee, D., Miglarese, M., Farmulok, Mayer, G., Spetzler, D. Poly-ligand Profiling Differentiates Trastuzumab-Treated Breast Cancer Patients According to their Outcomes. **Nature Communications**. March 2018. 9:1-9.
- Jaffee, L., Van Dang, C., Agus, D., Alexander, B., Anderson, K., Ashworth, **A., Barker A.**, Bastani, R., Bhatia, S., Bluestone, J., Brawley, O., Butte, A., Coit, D., Davidson, N., Davis, M., DePinho, R. Diasio, Draetta, G., Frazier, L., Futreal, A., Gambhir, S., Ganz, P., Garraway, L., Gerson, S., Gupta, S., Heath, J., Hoffman, R., Hudis, C. Hughes-Halbert, C., Ibrahim, R., Jadvar, H., Kavanagh, B., Kittles, R., Thu Le, Q., Lippman, S., Mankoff, D., Mardis, E., Mayer, D., McMasters, K., NeMeropol, N., Mitchell, B., Naredi, P., Ornish, D., Pawlik, T., Peppercorn, J., Pomper, M., Raghavan, D., Ritchie, C., Schartz, S., Sullivan R. Wahl, R., D. Wolchok, J., Wong, S., Yung, A. Future cancer research priorities in the USA: a *Lancet Oncology* Commission. **The Lancet Oncology**. November 2017. 18: Issue 11, PE653-E706.
- **Barker, A.** Alexander, A., Butte, A. and Futrel, A, 2017. "Priorities in Big Data and Enhanced Data Sharing" Part 14, In: Jaffee EM, Dang CV., Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker, et. Al., Future cancer research priorities in the USA: a Lancet Oncology Commission. *Lancet Oncol*. 2017 Nov;18(11): e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. PMID: 29208398; PMCID: PMC6178838
- **Barker, A.**, Compton C., Poste G. 2014. The National Biomarker Development Alliance (NBDA): Accelerating the Translation of Biomarkers to the Clinic. **Biomarkers in Medicine**. July 2014. 8(6):873-876.
- Abernethy, A. Abrahams, E. **Barker, A.**, Buetow, K., Burkholder, R., et al. Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to Progress. **Clinical Cancer Research**. February 2014. 20(5):1-6.
- Poste G, Compton CC, **Barker AD**. The National Biomarker Development Alliance: Confronting the poor productivity of biomarker research and development. **Expert Rev Mol Diagn**. 2015;15 (2):211-215.
- The AACR Cancer Progress Report Writing Committee; Sawyers, C., Abateshen, C., Anderson, K.; **Barker, A.**, Baselga, J., et al. ACCR Cancer Progress Report 2013. **Clinical**

- Cancer Research:** an official journal of the American Association for Cancer Research. September 2013. 19(Suppl 20): S4-S98.
- The Cancer Genome Atlas Research Network. (2013). (Barker, A.): Erratum: Corrigendum: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. **Nature**, 494(7438), 506-506. <https://doi.org/10.1038/nature11903>
 - Yee, D., Haddad, T., Albain, K., Barker, A.D., et al. Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development. **Journal of Clinical Oncology**. December 2012. 30(36):4584-6.
 - The Cancer Genome Atlas Research Network. (A. Barker). (2012). Erratum: Integrated genomic analyses of ovarian carcinoma. **Nature**, 490(7419), 292-292. <https://doi.org/10.1038/nature11453>
 - Chin, L., Meyerson, M., et al. Cancer Genome Atlas Research Network (**Barker, A.D.**): Integrated Genomic Analyses of Ovarian Carcinoma. **Nature**. June 2011. 474:609-15.
 - **Barker, A.** Q&A: Anna Barker on the Cancer Genome Atlas. **Cancer Discovery**. August 2011. 1(3):193.
 - Altshuler JS, Balogh E, **Barker A.**, Eck, S, Friend, S, Ginsberg, G, Herbst, R., Nass, s., Streeter, C., and Wagner, J. Opening up to precompetitive collaboration. **Science Translational Medicine**. October 2010. 2(52):1-4.
 - Farrell, D., Alper, J., Ptak, K., Panaro, N., Grodzinski, P., **Barker, A.** (2010). Recent Advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. **ACS Nano**, 4(2), 589-594. <https://doi.org/10.1021/nn100073g>.
 - Ptak, K., Farrell, D., Panaro, N., Grodzinski, P., **Barker, A.D.** The CNI alliance for nanotechnology in cancer: Achievement and path forward. **Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology**. 2010. 2(5):450-60.
 - The International Cancer Genome Consortium, Hudson, T., Warwick, A., Aretz, A., **Barker, A.**, Bell, C., et al. International Network of Cancer Genome Projects. **Nature**. April 2010. 464:993-8.
 - **Barker AD**, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. **Clinical Pharmacology Therapeutics**. May 2009. 86(1):97-100.
 - Chin L., Meyerson, M., et al. The Cancer Genome Atlas Research Network (**Barker, A.D.**): Comprehensive genomic characterization defines human glioblastoma genes and core pathways. **Nature**. September 2008 (Online). October 2008. 455(7216):1061-8.

- Kelloff, G. Sullivan, D. Wilson, W. **Barker, A.**, et al. FDG-PET Lymphoma Demonstration Project Invitational Workshop. **Academic Radiology**. March 2007. 14(3):330-9.
- Ferrari, M., **Barker, A.D.**, Downing, G. A cancer nanotechnology strategy. **Nanobiotechnology**. 2005. 1(2):129-31.
- Sigal, E.V., **Barker, A.D.**, Durant, J.R., Foti, M., Sharp, P.A., Stovall, E.L. Report from THE MARCH research task force: Commissioned by THE MARCH – Coming together to conquer cancer. September 25-6, 1998. **Oncologist**. 1999. 4(2):145-87.
- Sigal, E.V., **Barker, A.D.** (Co-Chairs and Eds.). Report from The March Research Task Force. **Cancer Research**. 1998. 58(23):5590-5627.

Early Career Research Manuscripts and Published Abstracts

- Ovejera, A.A., Houchens, D.P., **Barker, A.D.** Chemotherapy of human tumor xenografts in genetically athymic mice. **Annals of Clinical and Laboratory Science**. January 1978. 8(1):50-6.
- Ovejera, A.A., Houchens, D.P., **Barker, A.D.**, Venditti, J.M. Inactivity of DL-amygdalin against human breast and colon tumor xenografts in athymic (nude) mice. **Cancer Treatment Reports**. April 1978. 62(4):576-8.
- Ovejera, A.A., Timm, F.M., Houchens, D.P., **Barker, A.D.** Development of a nude mouse facility designed for large-scale drug evaluation and other cancer research activities. In: **Proceedings of Symposium on the use of athymic (nude) mice in cancer research**. Edited by D.P. Houchens and A.A. Ovejera. Gustav Fischer, Inc., New York, NY. 1977. pp. 39-48.
- Ovejera, A.A., Houchens, D.P., **Barker, A.D.** Sensitivity of a human colon tumor xenograft in nude (athymic) mice to various clinically active drugs. **Proc. 2nd International Workshop on Nude Mice**. 1977. Edited by T. Numura, N. Ohsawa, N. Tamoki, and K. Fujiwara, University of Tokyo Press, Tokyo/Gustav Fischer Verlag, Stuttgart, pp. 451-60.
- Dennis, A.J., **Barker, A.D.**, Rice, J.M. Activation of endogenous retroviruses and the histocompatibility complex in infection, immunity, and genetics. **University Park Press, Baltimore**. Edited by H. Friedman. 1977. pp. 103-116.
- **Barker, A.D.**, Dennis, A.J., Moore, V.S., Rice, J.M. Effects of thymosin on cytotoxicity and virus production in AKR mice. **Annals of the New York Academy of Sciences**. 1979. 332:70-80.
- **Barker, A.D.**, Immunotoxicology of Inhaled Environmental Pollutants. Abstract/Presentation: **Gordon Research Conference**. 1979.

- **Barker, A. D.**, Dennis, A. J., Moore, V. S. and Rice, J. M. Effects of Thymosin on Cytotoxicity and Virus Production in AKR Mice. **Annals of the New York Academy of Sciences**. 1979. 332:70–80
- Ovejera, A.A., D.P. Houchens, and **A.D. Barker**. Abstract/Presentation: Chemotherapy of human tumor xenografts in genetically athymic mice. **Association of Clinical Scientists**. 1977.
- **Barker, A.D.**, and V.S. Moore. 1976. Thymosin-mediated alterations of the cytotoxic response in young and aged AKR and C57BL/6 mice. Abstract/presentation: **Fed. Proc.** 35:625.
- **Barker, A.D.**, A.J. Dennis, and V.S. Moore. B-tropic and non-B-Tropic virus-producing tumor cells in immunosuppressed BALB/c mice. Abstract/Presentation: **Reticuloendothelial Soc.** 1976.
- Barker, A.D., Moore, V.S. Thymosin studies in AKR mice. **Abstract/Presentation: National Cancer Institute** Conference on Modulation of Host Resistance in the Prevention or Treatment of Induced Neoplasms. 1976.
- **Barker, A.D.**, Waksal, S.D. In vivo studies of differentiation of thymus derived leukemic cells. **Annals of the New York Academy of Sciences**. 1975. 249:484-91.
- **Barker, A.D.**, Moore, V.S. In vivo and in vitro effects of thymosin treatment in spontaneous and first transplant AKR leukemias. **Federation Proceedings**. 1975. 34(3):4563.
- **Barker, A.D.**, Waksal, S.D. In vivo studies of differentiation of thymus derived leukemic cells. **Annals of the New York Academy of Sciences**. 1975. 249:484-91.
- **Barker, A.D.**, Moore, V.S. In vivo and in vitro effects of thymosin treatment in spontaneous and first transplant AKR leukemias. **Federation Proceedings**. 1975. 34(3):4563.
- St. Pierre, R.L., Waksal, S.D., **Barker, A.D.**, Cohen, G., Goldstein, A. Presentation/Abstract: T-cell differentiation during antigen recognition and thymosin treatment in vitro. **Proc. 9th Leukocyte Culture Conference**. 1974.
- **Barker, A.D.**, Waksal, S.D. Thymus-derived lymphocyte differentiation and lymphocyte leukemias. I. Evidence for the existence of functionally different subpopulations of thymus-derived cells in leukemic and AKR mice. **Cellular Immunology**. 1974. 12:140-9.
- **Barker, A.D.**, Rheins, M.S., David, G.W., Wilson, H.E. Immunologic responsiveness of young AKR mice to iodoacetate and to iodoacetate-treated tumor cells. **Immunologic Communications**. February 1973. 2(4):343-52.
- Rheins, M.S, **Barker, A.D.** Therapeutic and immunologic effects of iodoacetate in mature AKR mice. **Experientia**. May 1973. 29(4):476-7.

- **Barker, A.D.**, M.S. Rheins, and R.L. St. Pierre. The effects of rabbit antimouse-brain-associated-O-serum on the immunologic responsiveness of AKR mice. **Cellular Immunology**. May 1973. 7(1):85-91.
- Barker, A.D., and R.M. Folk. Immunoprophylactic and immuno-therapeutic effects of iodoacetate and of neuraminidase treated P388 leukemia cells. **Fed. Proc.** 1973.
- Dennis, A.J., Wilson, H.E., Barker, A.D, Rheins, M.S. Interferon induction in normal and human lymphocyte cultures by tilorone hydrochloride. **Proceedings of the Society for Experimental Biology and Medicine**. January 1973 141(3), 782-5.
- **Barker, A.D.**, Rheins, M.S., et al. Immunologic responsiveness of young AKR mice to iodoacetate and iodoacetate-modified tumor cells. **Abs. Ann. Meet. ASM**. 1972. 279:126.
- **Barker, A.D.**, Rheins, M.S., Wilson, H.E. Tilorone hydrochloride: its effects on friend virus leukemia in mice. **Bact. Proc.** 1971. 120:188.
- Rheins, M.S., **Barker, A.D.**, Wilson, H.E. 1971. Therapeutic effects of a series of nonviral interferon inducers on viral-induced leukemia. **Canadian Journal of Microbiology**. October 1971. 17(10):1259-65.
- **Barker, A.D.**, Rheins, M.S., Wilson, H.E. 1971. Amelioration of friend virus leukemia by sequential administration of viral and nonviral interferon inducers. **Proceedings of the Society for Experimental Biology and Medicine**. August 1971. 137(3):981-7.

Scientific American

- Collins, F.S. and **A.D. Barker**. 2008. Mapping the Cancer Genome. **Scientific American, Special Edition**, New Answers for Cancer. 2008. 18(3):22-9.
- **Collins, F., Barker, A. D.** Mapping the Cancer Genome. **Scientific American**. April 2007. 296(3):50-7.

Book Chapters

- **Barker, A.D.** and H. Jordan. Section 22 Societal Oncology: The Government and Cancer Medicine. **Cancer Medicine**. 2003. Edited by D.W. Kufe, R. Pollock, R. Weichselbaum, R. Bast, T. Gansler, J. Holland, and E. Frei III. BC Decker Inc.
- **Barker, A.D.**, and H. Jordan. The Government and Cancer Medicine. **Cancer Medicine**. 2006. Edited by D.W. Kufe, R. Pollock, R. Weichselbaum, R. Bast, T. Gansler, J. Holland, and E. Frei III. BC Decker Inc.
- **Barker A.D.** Cancer biomarkers. In Goldman L, Ausiello DA, Arend W, Armitage JO, Clemmons D, Drazen J, Griggs, R, LaRusso N, Newman J, Foster, E, editors. **Cecil Medicine 23rd Edition**. 2007. Philadelphia: WB Saunders, pp. 1363–66.

Patents

Barker Anna D (US), Day Robert W (US), Dennis Anthony J (US), Farnsworth Norman R (US), Haack Julie A (US), Mccord Joseph M (US) Potter John D (US). National Center for Biotechnology Information (2021). PubChem Patent Summary for US-6646013-B1, Nutrient formulations for disease reduction. Retrieved March 26, 2021, from <https://pubchem.ncbi.nlm.nih.gov/patent/US-6646013-B1>.